Skip to content

User Study for Enhanced Meter Feature

User Study for the Evaluation of an Enhanced Meter Feature Using an AgaMatrix BGMS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01889355
Enrollment
121
Registered
2013-06-28
Start date
2014-01-31
Completion date
2014-03-31
Last updated
2018-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

diabetes, glucose, glucometer

Brief summary

This enhanced meter feature raises awareness among patients by providing additional information regarding their glycemic control in between Healthcare Professional visits. This information may facilitate increased dialogue between patient and Healthcare Professional and can remind patients of the importance of glycemic control. This study will evaluate a user's ability to use the enhanced meter feature.

Interventions

Sponsors

AgaMatrix, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

IC 1. Age of subject is 18 years or older IC 2. Type I or type II diabetes inclusive of the following populations: 1. Mixed insulin therapies 2. Basal insulin therapies 3. Bolus insulin therapies 4. CSII therapies 5. MDI therapies 6. Non-insulin diabetic treatments (oral and injectable) 7. Life style (exercise and diet) diabetes management IC 3. Able to speak and read English proficiently

Exclusion criteria

EC 1. Pregnant EC 2. Hct \<20 or \>60 EC 3. Work for BGM competitor company (including, but not limited to Lifescan, Roche, Abbott) EC 4. Homeless EC 5. Incarcerated EC 6. Institutionalized EC 7. Employees or students of the Research Site, including the Principal Investigator, directly involved in the conduct of the protocol. EC 8. Has any condition that the Principal Investigator believes may interfere in the subject's participation in the study. EC 9. Previous experience using the MyStar Extra BGMS

Design outcomes

Primary

MeasureTime frameDescription
Enhanced Meter Feature Usability4 weeksThe primary objective of this study is to evaluate that the intended users are able to obtain accurate blood glucose measurements when operating the blood glucose monitoring system, given only the training materials routinely provided with the system (ISO 15197:2013 8.1).

Countries

United States

Participant flow

Participants by arm

ArmCount
Demographics
Age group ranged from ages 18-86, Male and female with both Type 1 and Type 2 diabetics. Race was both white, black/African American and Hispanic who are able to read and understand English per the subject consent form.
113
Total113

Baseline characteristics

CharacteristicDemographics
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
38 Participants
Age, Categorical
Between 18 and 65 years
75 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
107 Participants
Sex: Female, Male
Female
55 Participants
Sex: Female, Male
Male
58 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 113
serious
Total, serious adverse events
0 / 113

Outcome results

Primary

Enhanced Meter Feature Usability

The primary objective of this study is to evaluate that the intended users are able to obtain accurate blood glucose measurements when operating the blood glucose monitoring system, given only the training materials routinely provided with the system (ISO 15197:2013 8.1).

Time frame: 4 weeks

Population: All diabetic subjects who volunteer for the study and qualify in accordance with the study inclusion and exclusion criteria, the user requirements established by the manufacturer for the blood-glucose system, and applicable regulatory requirements, shall be eligible to participate in the study

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Subject Population, Inclusion and ExclusionEnhanced Meter Feature Usability50 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026